Respiratory Syncytial Virus (RSV) Clinical Trials

A listing of Respiratory Syncytial Virus (RSV) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Featured trial
C3671008 Matisse

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.

  • 274 views
  • 03 Dec, 2021
  • 160 locations
None
A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years Including Adults at High Risk for Severe RSV Infection

Syncytial Virus (RSV) disease, compared to adults 65 years and above.

Accepts healthy volunteers
  • 0 views
  • 02 Dec, 2021
  • 27 locations
None
A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65 Years

The purpose of this study is to demonstrate non-inferiority in terms of humoral immune responses of Ad26.RSV.preF-based study vaccine lots representative of different aged vaccine in comparison to a non-aged Ad26.RSV.preF-based study vaccine lot.

  • 0 views
  • 03 Dec, 2021
  • 8 locations
None
Study to Evaluate the Efficacy Immunogenicity and Safety of RSVpreF in Adults.

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of RSVpreF in the prevention of moderate to severe LRTI-RSV in

Accepts healthy volunteers
  • 22 views
  • 05 Dec, 2021
  • 163 locations
None
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-24 Months

This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as a nasal spray. Specifically

Accepts healthy volunteers
  • 0 views
  • 01 Dec, 2021
  • 12 locations
None
A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 65 Years Old

The purpose of this study is to demonstrate non-inferiority in terms of humoral immune responses induced by vaccination with one dose of the Phase 3 clinical trial material (CTM) compared with one dose of the Phase 2b CTM.

Accepts healthy volunteers
  • 0 views
  • 03 Dec, 2021
  • 5 locations
None
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above

The purpose of this study is to assess the lot-to-lot consistency in terms of immunogenicity and evaluate the safety and reactogenicity of 3 lots of the RSVPreF3 OA investigational vaccine administered as a single dose in adults 60 years of age (YOA).

Accepts healthy volunteers
  • 0 views
  • 25 Nov, 2021
  • 18 locations
None
A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)

The purpose of the study is to evaluate the efficacy of rilematovir compared to placebo treatment with respect to the clinical outcome on the RSV Recovery Scale (RRS).

nasal congestion
cough
fever
rsv infection
respiratory tract infection
  • 13 views
  • 02 Dec, 2021
  • 248 locations
None
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

Reaction (RT-PCR) confirmed Respiratory Syncytial Virus (RSV)-mediated Lower Respiratory Tract Disease (LRTD) when compared to placebo in adults aged 60 years and above.

  • 3 views
  • 02 Dec, 2021
  • 51 locations
None
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

The purpose of this study is to evaluate the clinical lot-to-lot consistency of the respiratory syncytial virus (RSV) maternal (RSV MAT) vaccine administered to healthy non-pregnant women 18-49

Accepts healthy volunteers
  • 0 views
  • 23 Nov, 2021
  • 31 locations